← Browse by Condition
Medical Condition
chronic inflammatory demyelinating polyneuropathy
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2
NCT07027111 Phase 2
Recruiting
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
Enrollment
60 pts
Location
United States
Sponsor
Nuvig Therapeutics, Inc.
NCT06183645
Recruiting
Exploratory Study on Predicting CIDP Patients' Decline During IV Immunoglobulin Treatment Adaptation Feasibility.
Enrollment
40 pts
Location
Belgium
Sponsor
Centre Hospitalier Universitai...